Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Danny Rischin, MD, MBBS, FRACP, on the importance of the stratification by PD-L1 score

Director, Division of Cancer Medicine, Head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, The University of Melbourne, tells us why the stratification by PD-L1 score in Keynote-048 is important regarding outcomes in head and neck cancer

Tags: ASCO Conference CoverageHead & Neck

Published: 03 June 2019

Recent Videos: Head & Neck

video

Danny Rischin, MD, MBBS, FRACP, on the importance of the stratification by PD-L1 score

Director, Division of Cancer Medicine, Head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, The University of ...

video

Danny Rischin, MD, MBBS, FRACP, shares thoughts on Keynote-048 presented at ASCO 2019

Dr. Rischin, Director, Division of Cancer Medicine, Head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, The ...

Related Videos

video-image

Danny Rischin, MD, MBBS, FRACP, shares thoughts on Keynote-048 presented at ASCO 2019

video-image

Barbara Burtness, MD, on chemotherapy and post-operative radiation in H&C cancers

video-image

Barbara Burtness, MD, on bevacizumab and chemotherapy for treatment of metastatic H&C cancers

video-image

Barbara Burtness, MD, considers whether H&N patients should be routinely tested for PD-L1

video-image

Barbara Burtness, MD, discusses immunotherapies and treatment of head and neck cancers

video-image

Barbara Burtness, MD, shares her thoughts on the results of the LUX head and neck 2 study

video-image

Che-Kai Tsao, MD, elaborates on results from the TITAN study in mCRPC from ASCO '19

video-image

Sandip Patel, MD, on treatment in the 2nd line setting following PD-L1 targeting agents

video-image

Sandip Patel, MD, speculates on the impact of the RELAY trial presented at ASCO 2019

video-image

Che-Kai Tsao, MD, offers opinion on the results of the ENZAMET study in mHSPC

video-image

Che-Kai Tsao, MD, discusses the current application of biomarkers in renal cell carcinoma

video-image

Saad Usmani, MD, FACP, considers data in smoldering MM coming out of ASCO 2019

video-image

Parameswaran Hari, MD, speculates on whether KRD will replace stem cell transplant

video-image

Tomasz M. Beer MD, FACP, outlines results from Keynote-365 presented at ASCO 2019

video-image

Shirish Madhav Gadgeel, MBBS, on treating patients who have already received PD-L1 targeting agents

video-image

Che-Kai Tsao, MD, on deciding between I-O + TKIs combinations indicated for the treatment of RCC

video-image

Philip Philip MD, PhD, FRCP, on the APACT trial in surgically resected pancreatic adenocarcinoma

video-image

Sandip Patel, MD, describes the ideal patient to receive Alimta + Keytruda based on Keynote-189

video-image

Lowell L. Hart, MD, FACP, explains the mechanism of action for trilaciclib

video-image

Parameswaran Hari, MD, discusses the role of CAR-T therapy in multiple myeloma

video-image

Shirish Madhav Gadgeel, MBBS, offers opinion on the results of the RELAY trial from ASCO 2019

video-image

Josep Tabernero, MD, PhD, speculates on exciting clinical trial outcomes in gastric cancer

video-image

Tomasz M. Beer MD, FACP, considers the role of metformin in castrate-resistant prostate cancer

video-image

Michael B. Atkins, MD, regarding the long-term follow up of Checkmate-004 in metastatic melanoma

video-image

Lowell L. Hart, MD, FACP, regarding recent data investigating trilaciclib in SCLC

video-image

Parameswaran Hari, MD, considers whether isatuximab will become a viable option in MM

video-image

Shirish Madhav Gadgeel, MBBS, on the ideal patient to receive Alimta + Keytruda based on Keynote-189

video-image

Robert A. Figlin, MD, speculates on clinical advances in renal cell carcinoma

video-image

Marwan G. Fakih, MD, on combining regorafenib + checkpoint inhibition in advanced CRC

video-image

Nancy A. Dawson, MD, regarding preferred agents in the 2nd line setting in renal cell carcinoma

video-image

Paul M. Barr, MD, considers the role of CAR-T therapy in B-cell lymphomas

video-image

Michael B. Atkins, MD, on the role of IMDC classification in treatment decision-making

video-image

Tomasz M. Beer MD, FACP, on the efficacy of abiraterone + enzalutamide in mCRPC

video-image

Robert A. Figlin, MD, regarding the role of systemic therapy in oligometastatic RCC

video-image

Marwan G. Fakih, MD, on whether KRAS amplification predicts resistance to EGFR therapies

video-image

Nancy A. Dawson, MD, on selecting the appropriate I-O + TKI combo in the treatment of 1st line RCC

video-image

Vincent Chung, MD, shares details from the APACT study in pancreatic adenocarcinoma

video-image

Tomasz M. Beer MD, FACP, discusses outcomes from the TITAN study in mCSPC

video-image

Paul M. Barr, MD, elaborates on outcomes from the RESONATE trial in relapsed/refractory CLL

video-image

Michael B. Atkins, MD, comments on clinical trials investigating the use of I-O and TKIs in RCC

video-image

Saad Usmani, MD, FACP, regarding outcomes from the MAIA study presented at ASCO 2019

video-image

Che-Kai Tsao, MD, considers the various I-O and TKI combinations available for 1st line RCC

video-image

Josep Tabernero, MD, PhD, provides perspective on the POLO trial in pancreatic

video-image

Philip Philip MD, PhD, FRCP, on BRCA gene mutations & outcomes in pancreatic cancer

video-image

Sandip Patel, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Kristin Higgins, MD, offers opinion on the PACIFIC study in non-small cell lung cancer

video-image

Parameswaran Hari, MD, considers the implications of the CASSIOPEIA trial

video-image

Marwan G. Fakih, MD, regarding outcomes from the AMG 510 study

video-image

Shirish Madhav Gadgeel, MBBS, on treating non-squamous NSCLC patients expressing high PD-L1

video-image

Robert A. Figlin, MD, on I-O & TKIs available and indicated for the treatment of 2nd line RCC

video-image

Marwan G. Fakih, MD, on why AMG 510 seems promising in colorectal and lung cancers

video-image

Nancy A. Dawson, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Vincent Chung, MD, elaborates on BRCA mutations and pancreatic cancer

video-image

Tomasz M. Beer MD, FACP, tells us about the ENZAMET study in mHSPC

video-image

Paul M. Barr, MD, on data from the CLL-14 trial in chronic lymphocytic leukemia

video-image

Michael B. Atkins, MD, considers preferred agents in the treatment of RCC in the 2nd line

video-image

Saad Usmani, MD, FACP, compares IV daratumumab and subcutaneous daratumumab

video-image

Che-Kai Tsao, MD, regarding the evolving landscape of metastatic clear cell RCC

video-image

Josep Tabernero, MD, PhD, offers perspective on Keynote-062 in advanced gastroesophageal

video-image

Philip Philip MD, PhD, FRCP, discusses outcomes from the POLO trial in pancreatic cancer

video-image

Sandip Patel, MD, comments on the top stories in lung cancer from ASCO 2019

video-image

Kristin Higgins, MD, shares her interpretation of the PACIFIC study in unresectable NSCLC

video-image

Parameswaran Hari, MD, elaborates on the outcome from the ECOG trial in SMM

video-image

Shirish Madhav Gadgeel, MBBS, regarding the top stories in lung cancer from ASCO 2019

video-image

Robert A. Figlin, MD, considers combination I-O and TKIs indicated for the treatment of 1st line RCC

video-image

Marwan G. Fakih, MD, describes the role of KRAS inhibitors in colorectal cancer

video-image

Nancy A. Dawson, MD, regarding the ENZAMET study in mHSPC presented at ASCO '19

video-image

Vincent Chung, MD, shares outcomes from the POLO trial metastatic pancreatic cancer

video-image

Paul M. Barr, MD, offers opinion on ibrutinib in 1st line chronic lymphocytic leukemia

video-image

Michael B. Atkins, MD, on selecting I-O and TKI combinations for the treatment of 1st line RCC

video-image

Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial

video-image

Andre Goy, MD, explains how lenalidomide will impact the management of FL and MZL

video-image

Leonard Saltz, MD, offers opinion on the value of of liquid biopsy in colorectal cancer treatment

video-image

Andre Goy, MD, discusses the role of CAR-T therapy in lymphomas

video-image

Robert M. Rifkin, MD, FACP, speculates on the promise of bispecific antibodies in MM

video-image

Andre Goy, MD, shares the most exciting advances in lymphoma coming out of ASCO 2019

video-image

Debu Tripathy, MD, elaborates on the SOPHIA trial in HER+ metastatic breast cancer

video-image

Debra Patt, MD, MPH, MBA, outlines policies proposed to address drug pricing

video-image

Debu Tripathy, MD, regarding CDK 4/6 inhibitors in the treatment of breast cancer

video-image

Leonard Saltz, MD, offers opinion on molecular profiling in the treatment of CRC

video-image

Robert M. Rifkin, MD, FACP, discusses maintenance regimens for multiple myeloma

video-image

Debu Tripathy, MD, elaborates on outcomes from the ImPassion130 trial

video-image

Debra Patt, MD, MPH, MBA, considers the transition from volume to value in the oncology space

video-image

Debu Tripathy, MD, shares the outcomes of the MONALEESA-7 in premenopausal metastatic breast cancer

video-image

Thomas A. Abrams, MD, outlines next steps if an HCC patient fails 1st line therapy with I-O

video-image

Sara M. Tolaney, MD, MPH, on the efficacy & safety of combination eribulin + pembrolizumab

video-image

Paul G. Richardson, MD, shares clinical results from the ECOG trial in smoldering MM

video-image

Debra Patt, MD, MPH, MBA, on the factors influencing cost in novel therapeutic interventions

video-image

Leonard Saltz, MD, shares outcomes from the APACT trial in pancreatic adenocarcinoma

video-image

Robert M. Rifkin, MD, FACP, considers progression-free survival in MM when treating with isatuximab

video-image

Paul G. Richardson, MD, considers whether isatuximab shows promise as a treatment option for MM

video-image

Debra Patt, MD, MPH, MBA, considers the role of CDK 4/6 inhibitors in advanced breast cancer

video-image

Talia Golan, MD, explains the role of biomarkers in the treatment of pancreatic cancer

video-image

Thomas A. Abrams, MD, offers thoughts on Keynote-062 in gastric/gastroesophageal cancer

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the ImPassion130 study in TNBC

video-image

Leonard Saltz, MD, considers the complexities of managing metastatic colorectal cancer

video-image

Robert M. Rifkin, MD, FACP, explains how isatuximab differs from daratumumab

video-image

Paul G. Richardson, MD, considers progression-free survival in MM when treating with isatuximab

video-image

Debra Patt, MD, MPH, MBA, regarding the implications of the ImPassion130 trial in TNBC

video-image

Talia Golan, MD, regarding the practice-changing potential of the POLO trial

video-image

Thomas A. Abrams, MD, elaborates on the outcomes from the APACT study

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the MONALEESA-7 trial

video-image

Leonard Saltz, MD, on whether data presented at ASCO '19 will change the way we treat CRC

video-image

Robert M. Rifkin, MD, FACP, discusses outcomes from the ECOG trial in smoldering multiple myeloma

video-image

Paul G. Richardson, MD, regarding the updated FORTE trial data in multiple myeloma

video-image

Debra Patt, MD, MPH, MBA, on the important implications of the MONALEESA-7 trial

video-image

Talia Golan, MD, elaborates on the outcomes from the POLO study presented at ASCO 2019

video-image

Thomas A. Abrams, MD, provides perspective on the POLO trial in metastatic pancreatic cancer

video-image

Naiyer Rizvi, MD, speculates on the future of drug development in NSCLC

video-image

William Oh, MD, tells us about the results of Keynote-365 in mCRPC

video-image

Naiyer Rizvi, MD, offers thoughts on the role of blood TMB vs. tissue TMB

video-image

William Oh, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

Neelima Denduluri, MD, elaborates on the SOPHIA trial data in HER+ metastatic breast cancer

video-image

Daniel J. DeAngelo, MD, PhD, comments on how to manage MDS patients ineligible for transplant

video-image

Naiyer Rizvi, MD, describes the role of PD-L1 & TMB biomarkers in the treatment of lung cancer

video-image

William Oh, MD, considers the role of biomarker selection trials in prostate cancer

video-image

Andrew Goy, MD, explains how the approval of lenalidomide will impact the management of FL & MZL

video-image

Neelima Denduluri, MD, regarding the EMBRACA trial in HER2- metastatic breast cancer

video-image

Daniel J. DeAngelo, MD, PhD, considers the implications of the recent wave of approvals in AML

video-image

Naiyer Rizvi, MD, tells us about the results of Keynote-001 in NSCLC

video-image

William Oh, MD, shares the differences between the ENZAMET and TITAN studies

video-image

Andrew Goy, MD, discusses the role of CAR-T therapy in lymphomas

video-image

Neelima Denduluri, MD, discusses outcomes from the ImPassion130 trial

video-image

Daniel J. DeAngelo, MD, PhD, on the significance of the updated data for gilteritinib in AML

video-image

Naiyer Rizvi, MD, explains the role of biomarkers in lung cancer treatment planning

video-image

William Oh, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Andrew Goy, MD, elaborates on the most exciting recent clinical advances in lymphoma

video-image

Neelima Denduluri, MD, regarding the MONALEESA-7 trial in premenopausal metastatic breast cancer

video-image

Daniel J. DeAngelo, MD, PhD, on the latest data involving uproleselan with chemotherapy in AML

video-image

Bradley McGregor, MD, considers strategies for treating 2nd line RCC patients

video-image

Ravi Salgia, MD, PhD, considers the unmet medical needs in the treatment of NSCLC

video-image

Ravi Salgia, MD, PhD, on treatment in the 2nd line setting after 1st line PD-L1 targeting agents

video-image

Ravi Salgia, MD, PhD, on the ideal patient to receive Alimta plus Keytruda based on Keynote-189

video-image

Lori A. Leslie, MD, on the recent data regarding umbralisib in relapsed/refractory lymphoma

video-image

Lori A. Leslie, MD, speculates on how CAR-T cell therapy may be combined to treat lymphomas

video-image

Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer

video-image

Ravi Salgia, MD, PhD, on treating non-squamous, NSCLC patients with high levels of PD-L1

video-image

Tian Zhang, MD, discusses the most anticipated trial results regarding biomarkers in RCC

video-image

Ravi Salgia, MD, PhD, offers strategies for identifying PD-L1 status

video-image

Danny Rischin, MD, MBBS, FRACP, shares updated data from ASCO '19 investigating cemiplimab in cSCC

video-image

Tian Zhang, MD, regarding strategies for treating RCC in the 2nd line setting

video-image

Ravi Salgia, MD, PhD, outlines some of the molecular tests utilized prior to treating advanced NSCLC

video-image

Tian Zhang, MD, offers perspective on treating newly diagnosed RCC patients

video-image

Ravi Salgia, MD, PhD, comments on germline mutations & the impact on NSCLC patients

video-image

Bradley McGregor, MD, considers the optimal approach to treating newly diagnosed RCC patients

video-image

Richard S. Finn, MD, speculates on the next phase of HCC management and research

video-image

Imane El Dika, MD, outlines next steps if an HCC patient fails 1st line therapy

video-image

Edward B. Garon, MD, on the implications of Keynote-189

video-image

Richard S. Finn, MD, outlines the next steps if an HCC patient fails 1st line therapy

video-image

Imane El Dika, MD, considers the role of I-O in the management of HCC

video-image

Edward B. Garon, MD, elaborates on the role of PD-L1 in the management of lung cancer

video-image

Richard S. Finn, MD, offers opinion on the broader role of I-O in the management of HCC

video-image

Imane El Dika, MD, elaborates on the outcomes of Keynote-240 presented at ASCO 2019

video-image

Edward B. Garon, MD, considers the implications of Keynote-001 in advanced NSCLC

video-image

Richard S. Finn, MD, regarding outcomes from Keynote-240 in 1st line HCC

video-image

Pasi A. Jänne, MD, PhD, regarding the unmet medical needs in the treatment of NSCLC

video-image

Daneng Li, MD, elaborates on the COSMIC-312 trial in hepatocellular carcinoma

video-image

Pasi A. Jänne, MD, PhD, discusses some of the challenges in managing NSCLC

video-image

Martin E. Gutierrez, MD, discusses some of the top challenges in managing NSCLC

video-image

Daneng Li, MD, describes next steps if an HCC patient fails 1st line I-O therapy

video-image

Bruce Feinberg, DO, speculates on the future of AI in oncology treatment centers

video-image

Amrita Krishnan, MD, considers whether KRD will replace stem cell transplant

video-image

Pasi A. Jänne, MD, PhD, on treating patients in the 2nd line setting after 1st line Keytruda

video-image

Martin E. Gutierrez, MD, on 2nd line treatment options following 1st line PD-L1 targeting agents

video-image

Bruce Feinberg, DO, outlines some of the concerns that oncologists have regarding AI

video-image

Lori A. Leslie, MD, elaborates on recent outcomes from the CLL14 trial

video-image

Amrita Krishnan, MD, discusses the future of isatuximab in the treatment of relapsed/refractory MM

video-image

Pasi A. Jänne, MD, PhD, elaborates on outcomes from the RELAY trial

video-image

Martin E. Gutierrez, MD, discusses the implications of the RELAY trial from ASCO 2019

video-image

Bruce Feinberg, DO, on how AI may evolve as a clinical decision-making support tool

video-image

Amrita Krishnan, MD, regarding outcomes from the CASSIOPEIA trial presented at ASCO '19

video-image

Pasi A. Jänne, MD, PhD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Martin E. Gutierrez, MD, regarding the implications of the initial & updated results of Keynote-189

video-image

Bruce Feinberg, DO, on real-world examples of artificial intelligence applications in oncology

video-image

Kim Chi, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

Amrita Krishnan, MD, tells us about the outcomes of the ECOG trial in SMM

video-image

Kim Chi, MD, provides perspective on biomarker selection trials in prostate cancer

video-image

Daneng Li, MD, considers the role of immuno-oncology in the management of HCC

video-image

Pasi A. Jänne, MD, PhD, on molecular testing prior to the treatment of advanced NSCLC

video-image

Martin E. Gutierrez, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

video-image

Bruce Feinberg, DO, defines and considers artificial intelligence as a healthcare tool

video-image

Pasi A. Jänne, MD, PhD, on the study of U3-1402 in EGFR mutant NSCLC presented at ASCO 2019

video-image

Daneng Li, MD, tells us about the outcomes of Keynote 240 presented at ASCO 2019

video-image

Bradley McGregor, MD, on combo ipilimumab + nivolumab in variant histologies of bladder cancer

video-image

Lori A. Leslie, MD, on how CAR-T cell therapy has impacted the treatment of B-cell lymphomas

video-image

Kim Chi, MD, regarding the differences in design between the ENZAMET & TITAN studies

video-image

Tian Zhang, MD, on promising studies in sarcomatoid RCC & urothelial cancer from ASCO '19

video-image

Martin E. Gutierrez, MD, on the role of clinico-genomic data sharing in lung cancer treatment

video-image

Pasi A. Jänne, MD, PhD, on advances in the treatment of lung cancer being presented at ASCO 2019

video-image

Ravi Salgia, MD, PhD, offers opinion on the top challenges in managing NSCLC

video-image

Bruce Feinberg, DO, considers how artificial intelligence may help practices become more efficient

video-image

Tian Zhang, MD, shares thoughts on the PDIGREE trial in metastatic, untreated RCC

video-image

Bradley McGregor, MD, on the data regarding enfortumab in post-platinum + I-O bladder cancer

video-image

Kim Chi, MD, regarding the TITAN study presented at ASCO 2019

video-image

Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?

video-image

How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?

video-image

How Can a CAR-T Center Get Established and Effectively Treat Patients?

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Novel Endpoints: Working Through Today's Challenges to Improve the Future of Cancer Care

video-image

Novel Endpoints in Cancer Care: What Lies Ahead

video-image

Oncology Clinical Trials: Why We're Searching for Emerging Endpoints

video-image

Howard (Jack) West, MD, regarding Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients

video-image

Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab

video-image

NGS and Cancer: Combatting the Hazards of Misinformation

video-image

Will NGS-Based Cancer Tests Become Routine?

video-image

Next-Gen Sequencing is Transforming Oncology Practices

video-image

Howard (Jack) West, MD, discusses key takeaways from the IMpower150 study in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, considers predictive biomarkers in NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, on the outcomes of the PERSEPHONE clinical trial

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, regarding novel concepts in clinical trial design

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, shares his goals for the 2019 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, on the outcomes of the SANDPIPER study presented at ASCO 2018

video-image

Neelima Denduluri, MD, looks back on the Short-HER trial from the 2017 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancer

video-image

Neelima Denduluri, MD, tells us about the recent updates to breast cancer guidelines

video-image

Neelima Denduluri, MD, comments on the role of CDK4/6 inhibitors

video-image

Neelima Denduluri, MD, regarding the implications of the TAILORx study from ASCO 2018

video-image

Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC

video-image

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC

video-image

Robert A. Figlin, MD, provides perspective on I-O failures

video-image

Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy

video-image

Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients

video-image

Walter Stadler, MD, on therapies for high-volume, metastatic castration-resistant prostate cancer

video-image

Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms

video-image

Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer

video-image

Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma

video-image

Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure

video-image

Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy

video-image

David I. Quinn, MD, provides perspective on the trade-offs between safety & efficacy in 1st line RCC

video-image

David I. Quinn, MD, considers whether the convenience of oral TKIs impacts RCC treatment

video-image

David I. Quinn, MD, comments on 2nd line therapy options following I-O failure

video-image

David I. Quinn, MD, shares thoughts on Keynote 427 from the 2018 ASCO Annual Meeting

video-image

David I. Quinn, MD, regarding the most exciting RCC data coming out of ASCO 2018

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Jeanny B. Aragon-Ching, MD, FACP, comments on 2nd line treatment options in RCC after I-O failure

video-image

Jeanny B. Aragon-Ching, MD, FACP, on response rates for erdafitinib in metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, on molecular markers in high-risk muscle-invasive bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, discusses new guidelines in treatment of metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the impact of the PROSPER and SPARTAN clinical trials

video-image

Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection

video-image

Eunice Wang, MD, tells us about the most exciting data coming out of the 2018 ASCO Annual Meeting

video-image

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

video-image

Eunice Wang, MD, regarding evolving treatment considerations for FLT3 mutated AML

video-image

Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting

video-image

Eunice Wang, MD, considers the potential impact of gilteritinib in patients with FLT3-ITD AML

video-image

Eunice Wang, MD, on next-generation sequencing and treatment selection in AML

video-image

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

video-image

Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing

video-image

Gary D. Steinberg, MD, on whether FGFR inhibitors have the potential to be practice-changing

video-image

Bobby Green, MD, on next-generation sequencing and Flatiron's clinico-genomic database

video-image

Bobby Green, MD, shares an update on Flatiron’s clinico-genomic database

video-image

Bobby Green, MD, reflects on the 2018 ASCO Annual Meeting

video-image

Ghassan Abou-Alfa, MD, MBA, regarding the shortcomings of the RECIST study in HCC

video-image

Ghassan Abou-Alfa, MD, MBA, shares the outcomes of the CELESTIAL study from ASCO 2018

video-image

Ghassan Abou-Alfa, MD, MBA, considers how immunotherapies should be combined with TKIs

video-image

Ghassan Abou-Alfa, MD, MBA, on the latest in systemic therapy for advanced HCC

video-image

Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting

video-image

Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC

video-image

Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment

video-image

Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer

video-image

John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”

video-image

John Leighton, MD, regarding preoperative chemotherapy in resectable pancreatic cancer

video-image

John Leighton, MD, regarding the PA.6 clinical study presented at ASCO 2018

video-image

John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms

video-image

John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC

video-image

Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC

video-image

Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018

video-image

Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC

video-image

Primo N. Lara, Jr., MD, comments on which TKIs appear most effective in 1st line RCC

video-image

Primo N. Lara, Jr., MD, on whether the convenience of oral TKIs influences treatment decisions

video-image

Primo N. Lara, Jr., MD, considers the trade-offs between safety & efficacy in 1st line RCC treatment

video-image

Primo N. Lara, Jr., MD, regarding the treatment path following I-O failure

video-image

Primo N. Lara, Jr., MD, on deciding which mRCC patients should receive a TKI

video-image

Primo N. Lara, Jr., MD, on how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Celestia S. Higano, MD, considers the role of immunotherapy in prostate cancer

video-image

Celestia S. Higano, MD, discusses outcomes from the PROSPER and SPARTAN studies at ASCO 2018

video-image

Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab

video-image

Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC

video-image

Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018

video-image

Brian I. Rini, MD, FACP, comments on the CARMENA study presented at ASCO 2018

video-image

Brian I. Rini, MD, FACP, discusses the influence of the convenience of oral TKIs

video-image

Brian I. Rini, MD, FACP, regarding the trade-offs between safety & efficacy in 1st line RCC

video-image

Brian I. Rini, MD, FACP, considers 2nd line treatment in advanced RCC following I-O failure

video-image

Brian I. Rini, MD, FACP, on which metastatic RCC patients should receive a TKI as 1st line therapy

video-image

Brian I. Rini, MD, FACP, on how checkpoint inhibitors figure into treatment algorithms for RCC

video-image

James A. Posey III, MD, on the outcomes of the LAPACT study in locally advanced pancreatic cancer

video-image

James A. Posey III, MD, comments on the impact of immunotherapy agents in pancreatic cancer

video-image

James A. Posey III, MD, discusses the unmet medical needs in pancreatic ductal adenocarcinoma

video-image

James A. Posey III, MD, offers opinion on preoperative chemotherapy in resectable pancreatic cancer

video-image

James A. Posey III, MD, on the results and implications of the PA.6 clinical trial from ASCO 2018

video-image

Ivo Abraham, PhD, RN, comments on how we can demonstrate the value of cancer treatments

video-image

Ivo Abraham, PhD, RN, outlines biosimilar pricing and reimbursement

video-image

Ivo Abraham, PhD, RN, discusses those biosimilars that are approved or close to approval

video-image

Ivo Abraham, PhD, RN, speculates on the hurdles that could prevent the adoption of biosimilars

video-image

Ivo Abraham, PhD, RN, explains the key features of a biosimilar

video-image

Randall A. Oyer, MD, considers the work being done to address disparities in healthcare

video-image

Randall A. Oyer, MD, provides information on the ACCC Immuno-Oncology Institute

video-image

Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

Roy S. Herbst, MD, PhD, on if patient selection will change as a result of Keynote 42

video-image

Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment

video-image

Roy S. Herbst, MD, PhD, shares what's exciting here at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

Lisa Rometty on the collaboration between Watson and the VA Precision Oncology Program

video-image

Lisa Rometty shares some of the recent accomplishments of IBM's Watson

video-image

Lisa Rometty elaborates on Watson's role in clinical trial matching

video-image

Lisa Rometty regarding the impact of Watson on real-world evidence and clinical decision making

video-image

Lisa Rometty explains how augmented intelligence is helping oncologists better treat cancer patients

video-image

Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER

video-image

Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018

video-image

Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study

video-image

Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018

video-image

Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study

video-image

Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting

video-image

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer

video-image

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

video-image

Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors

video-image

Tomasz M. Beer, MD, on how immunotherapy is being integrated into CRPC treatment algorithms

video-image

Tomasz M. Beer, MD, on how the PROSPER and SPARTAN studies are impacting standard of care

video-image

Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer

video-image

Tomasz M. Beer, MD, on how to avoid under-diagnosing and over-diagnosing prostate cancer

video-image

Tomasz M. Beer, MD, discusses the central themes regarding prostate cancer here at ASCO 2018

video-image

Mark Levis, MD, PhD, discusses exciting data from the 2018 ASCO Annual Meeting

video-image

Mark Levis, MD, PhD, speculates on evolving treatment considerations for FLT3 mutated AML

video-image

Mark Levis, MD, PhD, discusses what we've learned about gilteritinib in FLT3 mutated AML patients

video-image

Mark Levis, MD, PhD, comments on measurable residual disease in relapsed/refractory AML

video-image

Mark Levis, MD, PhD, on factors influencing 1st line therapy in AML patients with FLT3 mutations

video-image

Mark Levis, MD, PhD, regarding the impact of next-generation sequencing in AML

video-image

Nicholas J. Vogelzang, MD, on imaging as an effective solution for prostate cancer diagnosis

video-image

Nicholas J. Vogelzang, MD, offers opinion on how MRI has improved diagnosing in prostate cancer

video-image

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancer

video-image

Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"

video-image

Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients

video-image

Richard Goldberg, MD, on how the FIRE-3 data in CRC presented at ASCO 2018 reinforces CALGB 80405

video-image

Richard Goldberg, MD, considers the value of preoperative chemotherapy in pancreatic cancer

video-image

Richard Goldberg, MD, regarding the outcomes of the PA.6 clinical study in pancreatic cancer

video-image

Jennie Crews, MD, MMM, FACP, regarding key initiatives for the ACCC Immuno-Oncology Institute

video-image

Joan Schiller, MD, regarding Keynote trials from ASCO 2018 & the influence on choice of therapy

video-image

Joan Schiller, MD, considers the validity of Tumor Mutation Burden (TMB) as a biomarker

video-image

Joan Schiller, MD, on the impact of Keynotes 189 & 42 on drug sequencing regimens

video-image

Joan Schiller, MD, regarding the results of Keynote 42 presented at the 2018 ASCO Annual Meeting

video-image

Joan Schiller, MD, considers the continuation of pemetrexed maintenance

video-image

Joan Schiller, MD, offers her opinion on Keynote 189 & PDL-1 expression and patient selection

video-image

Jennie Crews, MD, MMM, FACP, outlines the mission of the ACCC Immuno-Oncology Institute

video-image

Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018

video-image

Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing

video-image

Douglas W. Blayney, MD, discusses the implications of the TAILORx study

video-image

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

video-image

Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms

video-image

Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC

video-image

Al Benson III, MD, FACP, tells us about the outcomes of the ECOG-ACRIN study

video-image

Jennie Crews, MD, MMM, FACP, on how community oncology is embracing biomarkers

video-image

Noa Biran, MD, on combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma

video-image

Noa Biran, MD, considers whether VPd is effective in relapsed multiple myeloma

video-image

Noa Biran, MD, on the logistics involved in delivering CAR-T in the BB2121 study

video-image

Noa Biran, MD, on the impact of the BB2121 study in multiple myeloma

video-image

Noa Biran, MD, shares some of the exciting clinical advances presented at ASCO 2018

video-image

Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study

video-image

David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42

video-image

David R. Gandara, MD, on continuing pemextrexed maintenance

video-image

David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, discusses the impact of Keynote 189 & 42 on drug sequencing regimens

video-image

David I. Quinn, MD, on which metastatic RCC patients should receive a TKI as first-line therapy

video-image

Gary D. Steinberg, MD, discusses FGFR inhibitors in metastatic bladder cancer

video-image

Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study

video-image

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

video-image

Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”

video-image

Celestia S. Higano, MD, discusses new data being presented here at ASCO in metastatic CRPC

video-image

Celestia S. Higano, MD, discusses how MRI has improved the diagnosis of prostate cancer

video-image

Celestia S. Higano, MD, on imaging as a cost-effective solution for diagnosis of prostate cancer

video-image

Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients

video-image

Real-World Evidence: Can It Drive Differentiation and Demonstrate 'Value'?

video-image

Real-World Evidence Today and Tomorrow: The Role of Key Stakeholders

video-image

Real-World Evidence Compared to Randomized Clinical Trials

video-image

Real-World Evidence as a Mechanism for Patient-Centric Care

video-image

Practical Issues When Treating With Immunotherapy

video-image

Beyond PD-L1: In Search of Better Biomarkers

video-image

Evolving Immunotherapy Combinations

video-image

Aref Al-Kali, MD, regarding the Leukostat test in conjunction with midostaurin

video-image

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

David Siegel, MD, PhD, on pomalidomide as an effective salvage therapy for MM patients

video-image

David Siegel, MD, PhD, considers the effectiveness of CAR T-cell therapy in treating MM

video-image

David Siegel, MD, PhD, on pembrolizumab and lenalidomide in multiple myeloma treatment

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on identifying the best patients for Zytiga versus Xtandi

video-image

George Simon, MD, FACP, FCCP, on the Checkmate 032 & CTONG 1104 NSCLC studies presented at ASCO

video-image

George Simon, MD, FACP, FCCP, regarding the most impactful clinical studies on lung cancer at ASCO

video-image

Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib

video-image

Jeffrey Meyerhardt, MD, offers opinion on the effectiveness of SIRT in treatment of metastatic HCC

video-image

Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients

video-image

Jeffrey Meyerhardt, MD, on how immunotherapies are being studied in gastric & esophageal cancers

video-image

Christopher Logothetis, MD, offers opinion on the efficacy of the AR-V7 test

video-image

Christopher Logothetis, MD, explains how he identifies the right patients for Zytiga versus Xtandi

video-image

Christopher Logothetis, MD, regarding CHAARTED, STAMPEDE, and LATITUDE data from ASCO 2017

video-image

Christopher Logothetis, MD, speculates on the cost implications of abiraterone

video-image

Christopher Logothetis, MD, on why the results of the LATITUDE study will be practice changing

video-image

Edward Kim, MD, provides insight on how to use the PD-L1 biomarker to direct therapy

video-image

Edward Kim, MD, describes how immunotherapy combinations will be used in the near future

video-image

Edward Kim, MD, comments on gefitinib versus vinorelbine-cisplatin as adjuvant treatment in NSCLC

video-image

Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer

video-image

Edward Kim, MD, offers his opinion on the biggest news in lung cancer before and during ASCO 2017

video-image

Howard Hochster, MD, discusses the optimal duration of FOLFOX therapy in stage III colon cancer

video-image

Howard Hochster, MD, on the impact of SWOG 1406 in treating BRAF mutation positive CRC patients

video-image

Richard Goldberg, MD, FASCO, on the new FDA indication for pembrolizumab

video-image

Richard Goldberg, MD, FASCO, shares his impression of the adjuvant biliary tract study at ASCO 2017

video-image

Richard Goldberg, MD, FASCO, regarding the optimal duration of therapy in stage III colon cancer

video-image

Howard Hochster, MD, explains the impact of immunotherapies on gastric GE junction cancers

video-image

Howard Hochster, MD, regarding the new peri-operative regimen FLOT for gastric cancer

video-image

Richard Goldberg, MD, FASCO, defines “high-risk” and “low-risk” stage III colon cancer patients

video-image

Patricia Goldsmith describes new patient-focused initiatives presented at ASCO 2017

video-image

Patricia Goldsmith discusses the tools available for cancer patients on their journey

video-image

Patricia Goldsmith shares what CancerCare is doing to help patients with financial toxicity

video-image

Nancy Dawson, MD, compares the side effect profiles of abiraterone and chemotherapy

video-image

Nancy Dawson, MD, on how hormone-sensitive advanced prostate cancer should be treated

video-image

Nancy Dawson, MD, regarding the STAMPEDE study presented at ASCO 2017

video-image

Nancy Dawson, MD, shares her impressions of the LATITUDE study

video-image

Phil Bonomi, MD, on immunotherapy for treatment of SCLC and mesothelioma

video-image

Thaddeus Beck, MD, FACP, on how Watson for Clinical Trials Matching can increase practice efficiency

video-image

Thaddeus Beck, MD, FACP, explains how Watson for Clinical Trials Matching operates

video-image

Thaddeus Beck, MD, FACP, shares his experience working with Watson for Clinical Trials Matching

video-image

Phil Bonomi, MD, offers opinion on whether MET inhibitors are effective in metastatic NSCLC

video-image

Noa Biran, MD, on what physicians should be aware of when sequencing agents in treating MM

video-image

Noa Biran, MD, offers opinion on how personalized medicine will impact treatment of multiple myeloma

video-image

Noa Biran, MD, shares how immunotherapies are being integrated into MM treatment algorithms

video-image

Noa Biran, MD, reviews the data from ASCO regarding induction of newly diagnosed MM patients

video-image

Jack West, MD, shares his outlook on IDO inhibitors for treatment of lung cancer

video-image

Jack West, MD, on what we know about durvalumab in treatment of stage 3 NSCLC

video-image

Jack West, MD, considers the relevance of testing for PD-L1

video-image

Jack West, MD, discusses possible immunotherapy combination treatments in the near future

video-image

Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the potential of the AR-V7 test

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, considers data from CHAARTED, STAMPEDE, and LATTITUDE

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, speculates on the cost implications of abiraterone

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on the practice-changing results of the LATITUDE study

video-image

Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancer

video-image

Debu Tripathy, MD, shares his impressions of the MONALEESA-2 study

video-image

Debu Tripathy, MD, regarding the results of the MONARCH-2 study

video-image

Debu Tripathy, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Jeff Sharman, MD, offers perspective on CAR T-cell therapies for the treatment of NHL

video-image

Jeff Sharman, MD, shares results of the GENUINE phase 2 study presented at ASCO 2017

video-image

Jeff Sharman, MD, comments on emerging trends in CLL management

video-image

Randall Oyer, MD, describes how ACCC is supporting practices that are participating in OCM

video-image

Randall Oyer, MD, reveals the challenges and solutions his practice is finding as a result of OCM

video-image

Randall Oyer, MD, shares major themes emerging from the OCM

video-image

Randall Oyer, MD, on how OCM is helping the healthcare system transition from volume to value

video-image

Kathryn Kolibaba, MD, lists key takeaways from the lymphoma oral session at ASCO 2017

video-image

Kathryn Kolibaba, MD, shares the results of the MAGNIFY study presented at ASCO

video-image

Mohammad Jahanzeb, MD, FACP, comments on the differences between CDK 4/6 inhibitors

video-image

Mohammad Jahanzeb, MD, FACP, on immunotherapy and treatment of metastatic breast cancer

video-image

Mohammad Jahanzeb, MD, FACP, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Mohammad Jahanzeb, MD, FACP, on the impact of the APHINITY study presented at ASCO

video-image

Leonard Saltz, MD, reflects on intriguing CRC clinical data presented at ASCO 2017

video-image

Leonard Saltz, MD, shares thoughts on how to control rising drug prices without impacting value

video-image

Leonard Saltz, MD, offers opinion on the optimal duration of adjuvant chemotherapy in colon cancer

video-image

Leonard Saltz, MD, elaborates on what interventions could help alleviate financial toxicity

video-image

Leonard Saltz, MD, on how to begin the conversation with patients about financial toxicity

video-image

Philip Philip, MD, on the lenvatinib data in patients with unresectable HCC presented at ASCO 2017

video-image

Philip Philip, MD, considers the benefits of immunotherapy in treating gastrointestinal cancer

video-image

Philip Philip, MD, shares his impression of the capcitabine data in biliary cancers

video-image

Philip Philip, MD, reflects on the impact of PEGPH20 in met pancreatic cancer

video-image

Philip Philip, MD, on what we’ve learned about the duration of therapy in the adjuvant CRC setting

video-image

Daniel Petrylak, MD, offers recommendations for bladder cancer patients

video-image

Daniel Petrylak, MD, on treating bladder cancer patients progressing on checkpoint inhibitors

video-image

Daniel Petrylak, MD, discusses the role of checkpoint inhibition therapy in urothelial carcinoma

video-image

Daniel Petrylak, MD, on prostate cancer guidelines and the results of the LATITUDE study

video-image

Andrew Pecora, MD, FACP, CPE, shares how COTA and IBM Watson are working together

video-image

Andrew Pecora, MD, FACP, CPE, on the implications of healthcare and reimbursement reform

video-image

Andrew Pecora, MD, FACP, CPE, describes the movement to value-based reimbursement

video-image

Andrew Pecora, MD, FACP, CPE, on healthcare reform and the move from volume to value in oncology

video-image

Debra Patt, MD, MPH, MBA, on establishing a more informatics enabled oncology practice

video-image

Debra Patt, MD, MPH, MBA, speculates on upcoming changes in the 340B program

video-image

Debra Patt, MD, MPH, MBA, comments on how she sees the new administration addressing drug costs

video-image

Debra Patt, MD, MPH, MBA, offers opinion on incorporating liquid biopsy into patient management

video-image

Debra Patt, MD, MPH, MBA, on the repercussions if utilization management isn’t used properly

video-image

Debra Patt, MD, MPH, MBA, explains the concept and importance of utilization management

video-image

Andrew Norden, MD, speculates on the future of Watson for oncology

video-image

Andrew Norden, MD, on how physicians can take advantage of Watson’s expanding library of tumor types

video-image

Andrew Norden, MD, describes the clinical utility of Watson for oncology

video-image

Kathryn Kolibaba, MD, describes the results of the BRIGHT study in front-line indolent NHL patients

video-image

Sundar Jagannath, MD, on what we should know when sequencing agents in treating multiple myeloma

video-image

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

video-image

Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms

video-image

Sundar Jagannath, MD, discusses promising data from ASCO regarding multiple myeloma

video-image

Robert Figlin, MD, explains how checkpoint inhibitors are changing the way RCC is treated

video-image

Robert Figlin, MD, discusses sequencing when treating metastatic RCC patients

video-image

Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patients

video-image

Robert Figlin, MD, offers his opinion on interesting abstracts at ASCO 2017 related to RCC

video-image

Robert Figlin, MD, speculates on the changing landscape of RCC treatment

video-image

Neelima Denduluri, MD, discusses exciting new approaches to treating breast cancer

video-image

Neelima Denduluri, MD, describes how CDK 4/6 inhibitors impact breast cancer treatment

video-image

Neelima Denduluri, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Nevena Damjanov, MD, comments on identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, on the Phase 3 Checkpoint 459 trial studying nivolumab in HCC

video-image

Nevena Damjanov, MD, shares her impressions of lenvatinib data in 1st line uHCC presented at ASCO

video-image

Lyudmila Bazhenova, MD, on the progress being made towards successfully sequencing ALK inhibitors

video-image

Lyudmila Bazhenova, MD, on treating ALK+ lung cancer patients with ALK inhibitors

video-image

Lyudmila Bazhenova, MD, on differentiating between ALK inhibitors

video-image

Lyudmila Bazhenova, MD, speaks to the reliability and accuracy of ALK biomarkers

video-image

Aref Al-Kali, MD, on how hematologists will adopt midostaurin for FLT3+ AML patients

video-image

Aref Al-Kali, MD, on the data coming out of ASCO 2017 regarding FLT3 mutant AML patients

video-image

Aref Al-Kali, MD, offers perspective on treating elderly AML patients

video-image

Nevena Damjanov, MD, discusses new agents being studied for treatment of advanced HCC

video-image

Andrew Norden, MD, on how Watson for Clinical Trial Matching (CTM) operates

video-image

Jack West, MD, discusses PD-L1/PD-1 therapy in lung cancer treatment algorithms

video-image

Neelima Denduluri, MD, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Julie Brahmer, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

Julie Brahmer, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

David Ettinger, MD, talks about impact of immunotherapy in 1st line metastatic NSCLC patients

video-image

Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer

video-image

Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study

video-image

Alexander Perl, MD, on the toxicity in the phase 3 study evaluating CPX-351 (Vyxeos)

video-image

Alexander Perl, MD, on the role of immunotherapy in treating hematological malignancies

video-image

Tanios Bekaii-Saab, MD, on developing effective immunotherapies in CRC patients

video-image

Tanios Bekaii-Saab, MD, on progress in developing immunotherapies in non MSI- High CRC patients

video-image

David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients

video-image

David Gandara, MD, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients

video-image

Bert O’Neill, MD, on making immunotherapy more effective in mCRC

video-image

Barbara Burtness, MD on the Keynote-055 study in SCCHN patients

video-image

Robert A. Figlin, MD on clinical study that lead to approval of lenvatinib (Lenvima)

video-image

Laura Chow, MD interprets the overall survival benefit with Opdivo in the CheckMate-141 study

video-image

Alan Venook, MD on whether CALGB/SWOG 80405 study provides guidance on therapeutic regimen

video-image

Jennie R. Crews, MD talks about the goals of the ICLIO as developed by ACCC

video-image

Mark Levis, MD, on why the FLT3 target is important in AML

video-image

Mark Levis, MD, discusses the role of immunotherapy in treating hematological malignancies

video-image

Eunice S. Wang, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results

video-image

Value Tools at ASCO 2016: Building a Framework for Prime Time (Part 3)

video-image

David Ettinger, MD, provides practical advice related to PD-L1 testing in metastatic NSCLC patients

video-image

Tanios Bekaii-Saab, MD, on how clinicians factor economics into therapeutic decision making

video-image

Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016

video-image

Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies

video-image

Mark Levis, MD discusses importance of hitting the FLT3 target in AML patients with this mutation

video-image

Mark Levis, MD, discusses the role of checkpoint inhibitors in treating hematological malignancies

video-image

Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.

video-image

Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.

video-image

Julie Gralow, MD, on the KRISTINE study

video-image

Julie Gralow, MD, discusses the Monarch 1 study

video-image

Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016

video-image

Julie Brahmer, MD, provides practical advice related to PD-L1 testing in NSCLC patients

video-image

Julie Brahmer, MD, on the importance of overall cost of therapy

video-image

Julie Brahmer, MD, on the level of PD-L1 expression in selecting the appropriate agent in NSCLC

video-image

Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.

video-image

Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment

video-image

Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study

video-image

Eunice S. Wang, MD, discusses the Quantum First Study

video-image

Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML

video-image

Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important

video-image

Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

David Ettinger, MD, on cost of therapy when choosing agents for late stage lung cancer patients

video-image

David Ettinger, MD, on choosing between immunotherapy and chemotherapy in metastatic NSCLC patients

video-image

David Ettinger, MD, on the positioning of ramucirumab (Cyramza) for NSCLC

video-image

David Ettinger, MD, talks about levels of PD-L1 expression and agent selection

video-image

Aref Al-Kali, MD, discusses the toxicity of the CPX-351 (Vyxeos) in the phase III study

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) phase III results in subsets

video-image

Aref Al-Kali, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results on treatment

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Aref Al-Kali, MD, discusses the importance of specificity when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

Anthony El-Khoueiry, MD, talks results of nivolumab (Opdivo) trial in Hepatocellular Carcinoma (HCC)

video-image

Anthony El-Khoueiry, MD, discusses the pipeline of products in development for HCC

video-image

Anthony El-Khoueiry, MD, discusses management of Nexavar (Sorafenib) toxicities in HCC

video-image

Anthony El-Khoueiry, MD, discusses impact of new data on HCC Standard of care over last few years

video-image

Alexander Perl, MD discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Alexander Perl, MD, discusses Abstract 7008 results and Crenolanib potential activity

video-image

Alexander Perl, MD, discusses the Quantum First Study and potential implications

video-image

Alexander Perl, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, discusses the potential impact of potency when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, on importance of FLT3 and provides his perspective on inhibitor differences

video-image

Alexander Perl, MD, on FLT3 inhibitors in development and importance of hitting the FLT3 target

video-image

David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

Julie Brahmer, MD, on positioning of ramucirumab (Cyramza) post-platinum therapy in NSCLC patients

video-image

Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumab

video-image

Howard Hochster, MD on the economic benefit seen in CALGB/SWOG 80405

video-image

Howard Hochster, MD talks progress in the development of effective non MSI-High immunotherapies

video-image

Nevena Damianov, MD on the reasoning for studying PD-L1 inhibition in advanced HCC

video-image

Nevena Damianov, MD relays which late stage clinical studies will impact in advanced HCC

video-image

Nevena Damianov, MD interprets how new advanced HCC agents will integrate into HCC treatment

video-image

Jennie R. Crews, MD relays the unique side effects being seen with long-term use of immunotherapies

video-image

Jennie R. Crews, MD, explains if there is a stopping point where immunotherapy shouldn’t be used

video-image

Jennie R. Crews, MD, looks at long-term efficacy with immunotherapies

video-image

Jennie R. Crews, MD, discusses the broad applicability and limitations with immunotherapy

video-image

Laura Chow, MD, provides the rationale for studying PD-L1 inhibitors in SCCHN

video-image

Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker

video-image

Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies

video-image

Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies

video-image

Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy

video-image

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

video-image

Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results

video-image

Tanios Bekaii-Saab, MD, on performance status when selecting mCRC, 3rd line treatment therapy

video-image

Tanios Bekaii-Saab, MD, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC

video-image

Tanios Bekali-Saab, MD, on utilizing regorafenib (Stivarga) and trifluridine (Lonserf)

video-image

Tanios Bekali-Saab, MD, comments on sequencing of immunotherapeutic agents in mCRC patients

video-image

Tanios Bekaii-Saab, MD on MSI-High as an mCRC response predictor to nivolumab (Opdivo)

video-image

Tanios Bekali-Saab, MD, tells us whether KRAS is a definitive biomarker in mCRC patients

video-image

Alexander Perl, MD on treatment based on the Phase III study evaluating CPX-351 (Vyxeos) versus 7+3

video-image

Eunice S. Wang, MD, discusses the importance hitting the FLT3 target

video-image

David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients

video-image

Tanios Bekaii-Saab, MD on outcomes of CALGB/SWOG 80404 and potential impact

video-image

Tanios Bekaii-Saab, MD, comments on outcomes of CALGB/SWOG 80404 regarding primary site of tumor

video-image

Phil Bonomi, MD, on importance of checkpoint inhibitors in first-line NSCLC setting

video-image

Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond

video-image

Phil Bonomi, MD, discusses costs of new lung cancer therapies relative to duration of therapy

video-image

Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer

video-image

Mohammad Jahanzeb, MD, FACP speaks about testing for PD-L1 in the first-line NSCLC setting

video-image

Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies

video-image

Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole

video-image

Mark Levis, MD, discusses significance of the Quantum-R study

video-image

Mark Levis, MD, on the mechanism of action for CPX-351 (Vyxeos) and why is it promising in AML

video-image

Mark Levis, MD discusses patient subsets that have the most need for new therapeutic options in AML

video-image

Mark Levis, MD, comments on attributes of Crenolanib in relapsed FLT3 positive AML

video-image

Mark Levis, MD comments on the importance of hitting multiple FLT3 components such as ITD and D-835

video-image

Mark Levis, MD, on importance of potency and selectivity for treating FLT3 positive patients

video-image

Alan Venook, MD talks about treatment strategies based on site of primary tumor in CRC patients

video-image

Alan Venook, MD, explains the biological difference between left-sided and right-sided CRC tumors

video-image

Alan Venook, MD explains the outcome of phase 3 CALGB/SWOG 80405 study

video-image

Robert Figlin, MD discusses how lenvatanib will fit into the advanced RCC treatment algorithm

video-image

Robert Figlin, MD, discusses recent progress in the treatment of renal cell cancer (RCC)

video-image

Robert Filgin MD explains the importance of cabozantinib as a tool in the RCC armamentarium

video-image

Robert Filgin MD provides an update on nivolumab (Opdivo) in RCC

video-image

Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial

video-image

Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer

video-image

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

video-image

Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1

video-image

Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatment

video-image

Debu Tripathy, MD regarding the MONARCH 1 (abemaciclib) study

video-image

Jeffrey A. Meyerhardt, MD explains results from the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD discusses the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD explains how OS from primary site of tumor may impact treatment

video-image

Jeffrey A. Meyerhardt, MD on the reliability of MSI-High as a predictor of response in mCRC

video-image

Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients

video-image

Jeffrey A. Meyerhardt, MD explains integration of Stivarga and Lonserf in later lines of treatment

video-image

Jeffrey A. Meyerhardt, MD weighs in on the economic vs efficacy outcomes in CALGB/SWOG 80405

video-image

Jeffrey A. Meyerhardt, MD, explains matching mutations and markers to therapies in CRC patients

video-image

Philip Philip, MD on Stivarga (regorafenib) dosage in 2nd line treatment of mCRC

video-image

Philip Philip, MD explains how to integrate regorafenib and trifluridine for 2nd line mCRC treatment

video-image

Philip Philip, MD on the importance of ipilimumab prior to nivolumab in mCRC patients

video-image

Philip Philip, MD on the reliability of MSI-High as a predictor of response to Opdivo in mCRC

video-image

Philip Philip, MD discusses phase 3 CALGB/SWOG 80405 study outcomes

video-image

Philip Philip, MD on what is impressing him at ASCO 2016 in CRC

video-image

Nevena Damianov, MD illustrates the promising classes and products for advanced, unresectable HCC

video-image

Nevena Damianov, MD discusses the toxicity concerns and how to manage them for sorafenib in HCC

video-image

Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents

video-image

Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016

video-image

Laura Chow, MD tells us about products in development for SCCHN

video-image

Laura Chow, MD discusses cross trial comparisons with Keytruda and Opdivo in head and neck cancers